The Novasecta Global 100
The Novasecta Global 100 is a comprehensive look at how the world’s top pharma companies are shaping the future of healthcare. Our report analyses the companies as whole entities rather than pharma business alone in order to fully explore the impact of their diverse business models and choices. We cover their performance across multiple dimensions, their […]
Defragmenting R&D: Lessons from the Pioneers
Effective Research and Development (R&D) is the lifeblood of the pharmaceutical industry. The funding of this highly risky and long-term activity had until the last decade or so been primarily left to well-capitalised and integrated global Big Pharma companies. A more recent era of cheap money has now changed all that. Since the market crash […]
Medical Affairs: Influencers of the Future
Medical Affairs is in the midst of an exciting metamorphosis. The global shift towards evidence-based care is creating new opportunities for the function to play a more strategic role within pharmaceutical companies. As medicines become more targeted and the evidence base more nuanced, Medical Affairs has the potential to become one of the key influencers […]
Breakthrough Innovation: Lessons for Pharma R&D
The realities of unrelenting price pressure and patent expiries put a special pressure on pharmaceutical companies to consistently create new and differentiated medicines. Pharma companies are compelled to innovate in order to survive, and the rewards for successful innovation are substantial. To understand the magic of innovation in pharma today, we have explored the lessons […]
How Ownership Influences Pharma Strategies
The advantages of being a privately owned or publicly listed pharma company continues to polarise opinion. A key consideration in this debate is the influence of ownership structure on company evolution and growth. While private, smaller pharma companies are thought to be more agile, publicly listed companies are considered to have more scaling opportunities. Our […]
Pharma M&A is Too Expensive: Now What?
M&A has become an increasingly expensive method of securing new assets, capabilities and growth for pharmaceutical companies. This has been a natural consequence of the combination of an abundance of cheap capital with the relentless ticking clock of patent expiries. Cheap capital puts pressure on large firms to “do something”, and in most cases acquiring […]
Integrated and Open Innovation: The Best of Both Worlds
Pharmaceutical companies continue to embrace the concept of leveraging innovation from external sources to build and balance their internal R&D pipelines. However, management systems that are geared towards progressing internal assets struggle to cope with the challenge of dealing with outside parties. This means that open innovation is often assigned to a new group of […]
Continued innovation pays for Big Pharma (CNBC)
In light of the announcement of Novartis’ and Pfizer’s Q4 results, John Rountree, was invited on CNBC to discuss innovation in the pharmaceuticals market. John highlights the continued strategic drive towards traditional innovation, which helps companies avoid the dangers of being a “one product company” and allows them to protect themselves from the risks of […]
Commercial and R&D: Value Lost in Translation?
Aligning R&D activities with commercial realities is an issue as old as the pharmaceutical industry itself. But it’s no closer to being solved. The importance of a commercial perspective in R&D is only growing as the downward pressure on drug prices and limitations on market access from payers continue to increase. In parallel, as pharmaceutical […]
Better Partnerships: The Alternative to M&A?
In a world of low-cost capital and investor pressure for earnings growth, M&A is still top of the agenda for senior pharmaceutical executives. But it is the more creative world of partnerships – through the likes of licensing, co-development, capability and risk sharing, technology collaborations and joint ventures – that has been a potent force […]